Xeris Biopharma (NASDAQ:XERS) Stock Rating Upgraded by Wall Street Zen

Xeris Biopharma (NASDAQ:XERS) was upgraded by Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued on Saturday, Wall Street Zen reports.

Other equities analysts have also issued research reports about the company. Barclays raised their price target on Xeris Biopharma from $12.00 to $14.00 and gave the company an “overweight” rating in a research note on Tuesday, October 6th. HC Wainwright boosted their price objective on shares of Xeris Biopharma from $10.00 to $18.00 and gave the company a “buy” rating in a research note on Friday. Oppenheimer reaffirmed an “outperform” rating and set a $21.00 target price (up from $18.00) on shares of Xeris Biopharma in a research note on Friday. Weiss Ratings downgraded shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Finally, Piper Sandler reiterated a “neutral” rating and set a $12.00 target price (up from $8.00) on shares of Xeris Biopharma in a research report on Friday. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $16.20.

Xeris Biopharma Stock Performance

XERS opened at $15.20 on Friday. The business’s fifty day moving average is $9.62 and its 200-day moving average is $7.62. Xeris Biopharma has a 52-week low of $5.25 and a 52-week high of $15.21. The firm has a market cap of $2.77 billion, a P/E ratio of -303.94 and a beta of 0.61. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.02 and a current ratio of 1.45.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings results on Thursday, November 5th. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. The business had revenue of $107.23 million for the quarter, compared to the consensus estimate of $101.68 million. Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. Sell-side analysts expect that Xeris Biopharma will post 0.07 EPS for the current fiscal year.

Insider Buying and Selling

In other Xeris Biopharma news, insider Kevin McCulloch sold 25,000 shares of the company’s stock in a transaction on Monday, September 28th. The shares were sold at an average price of $10.00, for a total transaction of $250,000.00. Following the completion of the transaction, the insider directly owned 1,614,208 shares in the company, valued at approximately $16,142,080. This represents a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Steven Pieper sold 5,000 shares of the stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $10.23, for a total transaction of $51,150.00. Following the completion of the transaction, the insider directly owned 1,346,053 shares in the company, valued at $13,770,122.19. This trade represents a 0.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 173,332 shares of company stock worth $1,721,471. 4.35% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vilga Financial Planning LLC acquired a new position in Xeris Biopharma in the third quarter worth about $10,134,000. Legal & General Group Plc bought a new position in shares of Xeris Biopharma during the second quarter worth approximately $15,941,000. Walleye Capital LLC bought a new stake in shares of Xeris Biopharma during the 2nd quarter valued at $4,841,000. Canada Pension Plan Investment Board bought a new stake in shares of Xeris Biopharma during the 2nd quarter worth $1,736,000. Finally, Bank of America Corp DE acquired a new position in shares of Xeris Biopharma in the second quarter valued at approximately $11,065,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Key Headlines Impacting Xeris Biopharma

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Q3 results beat expectations: Xeris reported earnings of $0.06 per share versus a $0.03 consensus estimate, while revenue of $107.23 million exceeded forecasts of $101.68 million. The results provide evidence of stronger-than-expected performance. Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
• Positive Sentiment: Analysts raised targets: Oppenheimer reaffirmed its “outperform” rating and lifted its target to $21 from $18. HC Wainwright kept a “buy” rating and raised its target to $18 from $10. These revisions suggest greater optimism about Xeris’s prospects. Oppenheimer ratings HC Wainwright ratings
• Positive Sentiment: Recorlev sales outlook: CEO John Shannon reportedly sees the drug approaching $1 billion in annual sales three to four years earlier than previously expected, a potentially meaningful growth driver. CEO comments on Recorlev sales outlook
• Neutral Sentiment: Insider Kevin McCulloch sold 25,000 shares under a pre-arranged Rule 10b5-1 plan, a modest reduction; he retained more than 1.55 million shares. SEC Form 4 filing
• Negative Sentiment: Cautious analyst view: Piper Sandler reaffirmed “neutral” despite raising its target to $12 from $8. That target remains below the share price cited in the report, signaling valuation concerns. Piper Sandler ratings

Xeris Biopharma Company Profile

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.